Federal Register / Vol. 86, No. 119 / Thursday, June 24, 2021 / Notices 33321 

Opportunity on (770) 488–3210 as soon 

as possible. 

SUPPLEMENTARY INFORMATION: On July 

14, 2021, the National Committee on 

Vital and Health Statistics (NCVHS), 

Subcommittee on Privacy, 

Confidentiality, and Security, will seek 

input from experts to examine solutions 

for improving the security posture of the 

healthcare industry. At the hearing, the 

Subcommittee will hear from invited 

experts on the range of security 

challenges affecting the health care 

industry and business partners. The 

Subcommittee will also hear about the 

range of policy options that may be 

available to the Department of Health 

and Human Services (HHS) and data 

stewards to improve the security 

posture of those organizations holding 

individually identifiable information 

(III), including federal, state, local, and 

tribal organizations. 

The Committee will use this input to 

identify and describe the changing 

security landscape and risks to the 

privacy and security of III held by the 

health care industry and highlight 

promising policies, practices, and 

technologies. The Committee will lay 

out integrative models for how best to 

secure individually identifiable 

information while enabling beneficial 

uses, services, and technologies. The 

Committee will formulate 

recommendations for the Secretary on 

actions that HHS might take and prepare 

a report for the Secretary. 

The Committee requests comments 

from the public in advance of the 

hearing to inform its deliberations and 

will consider them together with the 

input of subject matter experts at the 

hearing. Please submit comments to 

NCVHSmail@cdc.gov by close of 

business Tuesday, July 13, 2021. There 

also will be a public comment period at 

the meeting. The meeting times and 

topics are subject to change. Please refer 

to the NCVHS website for information 

and agenda updates. 

Sharon Arnold, 

Associate Deputy Assistant Secretary for 

Planning and Evaluation, Science and Data 

Policy, Office of the Assistant Secretary for 

Planning and Evaluation. 

[FR Doc. 2021–13329 Filed 6–23–21; 8:45 am] 

BILLING CODE 4150–05–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Delivery of a 

Corrective Glucose-6-PhosphataseAlpha Gene to Treat Glycogen Storage 

Disease Type 1a (GSD-Ia) in Humans 

AGENCY: National Institutes of Health, 

DHHS. 

ACTION: Notice. 

SUMMARY: The National Institute of 

Child Health and Human Development, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

U.S. and foreign Patents and Patent 

Applications listed in the 

Supplementary Information section of 

this notice to Panacea Opportunity, Ltd. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Institute of 

Child Health and Human Development 

c/o National Cancer Institute’s 

Technology Transfer Center on or before 

July 9, 2021 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Alan Hubbs, Ph.D., Senior 

Technology Transfer Manager at 

Telephone: (240)–276–5530 or Email: 

hubbsa@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

following represents the intellectual 

property to be licensed under the 

prospective agreement: 

Intellectual Property 

1. Priority Application, U.S.P.T.O. No. 

62/096,400, filed December 23, 2014 

[HHS Reference No. E–039–2015/0–US– 

01]; 

2. PCT Patent Application No. PCT/ 

US2015/067338, filed December 22, 

2015 [HHS Reference No. E–039–2015– 

0–PCT–02]; 

3. Pending Canadian Patent 

Application No. 2972038, filed on 

December 22, 2015, [HHS Reference No. 

E–039–2015–0–CA–03]; 

4. Issued China Patent No. 

ZL201580076462.4, filed on December 

22, 2015, Issued December 11, 2020 

[HHS Reference No. E–039–2015–0– 

CN–04]; 

5. Issued European Patent No. 

2182936, filed December 22, 2015, 

Issued July 22, 2020 [HHS Reference No. 

E–039–2015–0–EP–05]; 

6. Issued Israeli Patent No. 253103, 

filed on December 22, 2015, Issued 

April 1, 2020 [HHS Reference No. E– 

039–2015–0–IL–06]; 

7. Issued Japan Patent No. 6824169, 

filed June 22, 2017, Issued January 14, 

2021 [HHS Reference No. E–039–2015– 

0–JP–07]; 

8. Issued United States Patent No. 

10,415,044, filed September 17, 2019, 

Issued September 17, 2019 [HHS 

Reference No. E–039–2015–0–US–08] 

9. Pending United States Patent 

Application No. 16/526,327, filed July 

30, 2019, [HHS Reference No. E–039– 

2015–0–US–08] 

With respect to persons who have an 

obligation to assign their right, title and 

interest to the Government of the United 

States of America, the patent rights in 

these inventions have been assigned to 

the Government of the United States of 

America. The prospective exclusive 

license territory may be world-wide, 

and the field of use may be limited to 

the use of Licensed Patent Rights for the 

following: ‘‘Delivery of a corrective 

glucose-6-phosphatase-alpha gene to 

treat glycogen storage disease type 1a 

(GSD-Ia) in humans.’’ 

This technology discloses a gene 

therapy to treat glycogen storage disease 

type 1a (GSD-Ia) in humans using 

adeno-associated virus mediated 

delivery of a corrective glucose-6- 

phosphatase-alpha (G6Pase-a) gene 

nucleic acid sequence that codes for a 

protein having an amino acid sequence 

that differs from the wildtype human 

amino acid sequence at amino acid 

position 293. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Institute of Child Health and Human 

Development receives written evidence 

and argument that establishes that the 

grant of the license would not be 

consistent with the requirements of 35 

U.S.C. 209 and 37 CFR part 404. In 

response to this Notice, the public may 

file comments or objections. Comments 

and objections, other than those in the 

form of a license application, will not be 

treated confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 


khammond on DSKJM1Z7X2PROD with NOTICES
33322 Federal Register / Vol. 86, No. 119 / Thursday, June 24, 2021 / Notices 

Dated: June 11, 2021. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2021–13261 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Advisory 

General Medical Sciences Council, 

September 01, 2021, 09:30 a.m. to 

September 02, 2021, 05:00 p.m., 

National Institutes of Health, Natcher 

Building, 6707 Democracy Boulevard, 

Bethesda, MD 20892 which was 

published in the Federal Register on 

December 31, 2020, FR Doc 2020– 

28902, 85 FR 86940. 

The meeting notice is amended to 

change the meeting date and time from 

September 1–2, 2021, 9:30 a.m. to 5:00 

p.m. to September 9, 2021, 9:00 a.m. to 

4:30 p.m. The meeting is partially 

closed to the public. 

Dated: June 14, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13377 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Newborn Screening 

Pilot Studies. 

Date: August 6, 2021. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, NIH, 6710 B Rockledge Drive, 

Rm. 2131D, Bethesda, MD 20817 (Telephone 

Conference Call). 

Contact Person: Sathasiva B. Kandasamy, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, NIH, 6710B Rockledge 

Drive, Rm. 2131D, Bethesda, MD 20817, (301) 

435–6680, skandasa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.865, Research for Mothers 

and Children, National Institutes of Health, 

HHS) 

Dated: June 14, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13348 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Program Project 

Grants for HIV Research in Perinatal HIV, 

Birth Outcomes and Neurodevelopment. 

Date: July 22–23, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development, NIH, 6710B Rockledge Drive, 

Room 2131B, Bethesda, MD 20897 (Video 

Assisted Meeting). 

Contact Person: Luis E. Dettin, Ph.D., M.S., 

M.A., Scientific Review Officer, Scientific 

Review Branch, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, NIH, 6710B Rockledge 

Drive, Rm. 2131B, Bethesda, MD 20892, (301) 

827–8231, luis_dettin@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.865, Research for Mothers 

and Children, National Institutes of Health, 

HHS) 

Dated: June 14, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13353 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Minority Health 

and Health Disparities; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Minority Health and Health Disparities 

Special Emphasis Panel; Coordinating Center 

for Multiple Chronic Disease Disparities 

Research Centers (U24). 

Date: July 15, 2021. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Gateway Plaza, 7201 Wisconsin Ave., 

Bethesda, MD 20817 (Virtual Meeting). 

Contact Person: Ivan K. Navarro, Ph.D., 

Scientific Review Officer, Office of 

Extramural Research Administration, 

National Institute on Minority Health and 

Health Disparities, National Institutes of 

Health, Gateway Building, 7201 Wisconsin 

Avenue, Bethesda, MD 20892, 301–827– 

2061, ivan.navarro@nih.gov. 

Dated: June 15, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13339 Filed 6–23–21; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES